Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35 (2013), Issue 2, Pages 73–78
http://dx.doi.org/10.1155/2013/301415
Clinical Study

HLA Markers for Poor Prognosis in Systemic Sclerosis Brazilian Patients

1Unit of Rheumatology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, SP, Brazil
2Division of Rheumatology, University of São Paulo School of Medicine (USP), São Paulo, SP, Brazil

Received 19 June 2012; Revised 19 June 2013; Accepted 4 July 2013

Academic Editor: Sun-Il Hwang

Copyright © 2013 Ana Paula Toledo Del Rio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Chifflot, B. Fautrel, C. Sordet, E. Chatelus, and J. Sibilia, “Incidence and prevalence of systemic sclerosis: a systematic literature review,” Seminars in Arthritis and Rheumatism, vol. 37, no. 4, pp. 223–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. S. Bernatsky, L. Joseph, C. A. Pineau, P. Belisle, M. Hudson, and A. E. Clarke, “Scleroderma prevalence: demographic variations in a population-based sample,” Arthritis Care and Research, vol. 61, no. 3, pp. 400–404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. V. D. Steen and T. A. Medsger, “Changes in causes of death in systemic sclerosis, 1972–2002,” Annals of the Rheumatic Diseases, vol. 66, no. 7, pp. 940–944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. D. Gladman, T. N. Kung, F. Siannis, F. Pellett, V. T. Farewell, and P. Lee, “HLA markers for susceptibility and expression in scleroderma,” Journal of Rheumatology, vol. 32, no. 8, pp. 1481–1487, 2005. View at Google Scholar · View at Scopus
  5. M. Kuwana, J. Kaburaki, Y. Okano, H. Inoko, and K. Tsuji, “The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma),” Journal of Clinical Investigation, vol. 92, no. 3, pp. 1296–1301, 1993. View at Google Scholar · View at Scopus
  6. F. K. Tan, D. N. Stivers, F. C. Arnett, R. Chakraborty, R. Howard, and J. D. Reveille, “HLA haplotypes and microsatellite polymorphisms in and around the major histocompatibility complex region in a Native American population with a high prevalence of scleroderma (systemic sclerosis),” Tissue Antigens, vol. 53, no. 1, pp. 74–80, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. J. D. Reveille, M. Fischbach, T. McNearney et al., “Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants,” Seminars in Arthritis and Rheumatism, vol. 30, no. 5, pp. 332–346, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Frezza, V. Giambra, B. Tolusso et al., “Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency,” Annals of the Rheumatic Diseases, vol. 66, no. 9, pp. 1210–1215, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. L. S. Loubière, N. C. Lambert, M. M. Madeleine et al., “HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women,” Rheumatology, vol. 44, no. 3, pp. 318–322, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. C. P. Simeón, V. Fonollosa, C. Tolosa et al., “Association of HLA class II genes with systemic sclerosis in Spanish patients,” Journal of Rheumatology, vol. 36, no. 12, pp. 2733–2736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. R. Karp, N. Marthandan, S. G. E. Marsh et al., “Novel sequence feature variant type analysis of the HLA genetic association in systemic sclerosis,” Human Molecular Genetics, vol. 19, no. 4, pp. 707–719, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Beretta, B. Rueda, M. Marchini et al., “Analysis of class II human leucocyte antigens in Italian and Spanish systemic sclerosis,” Rheumatology, vol. 51, no. 1, pp. 52–59, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. F. C. Arnett, P. Gourh, S. Shete et al., “Major histocompatibility complex (MHC) class II alleles, haplotypes and epitopes which confer susceptibility or protection in systemic sclerosis: analyses in 1300 Caucasian, African-American and Hispanic cases and 1000 controls,” Annals of the Rheumatic Diseases, vol. 69, no. 5, pp. 822–827, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Kuwana, Y. Okano, J. Kaburaki, and H. Inoko, “HLA class II genes associated with anticentromere antibody in Japanese patients with systemic sclerosis (scleroderma),” Annals of the Rheumatic Diseases, vol. 54, no. 12, pp. 983–987, 1995. View at Google Scholar · View at Scopus
  15. N. C. Lambert, O. Distler, U. Müller-Ladner, T. S. Tylee, D. E. Furst, and J. L. Nelson, “HLA-DQA1*0501 is associated with diffuse systemic sclerosis in Caucasian men,” Arthritis Rheum, vol. 43, pp. 2005–2010, 2000. View at Google Scholar
  16. T. R. D. J. Radstake, O. Gorlova, B. Rueda et al., “Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus,” Nature Genetics, vol. 42, pp. 426–429, 2010. View at Google Scholar
  17. X. Zhou, J. E. Lee, F. C. Arnett et al., “HLA-DPB1 and DPB2 are genetic loci for systemic sclerosis: a genome-wide association study in Koreans with replication in North Americans,” Arthritis and Rheumatism, vol. 60, no. 12, pp. 3807–3814, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. J. D. Reveille, E. Durban, M. J. MacLeod-St. Clair et al., “Association of amino acid sequences in the HLA-DQB1 first domain with the antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis),” Journal of Clinical Investigation, vol. 90, no. 3, pp. 973–980, 1992. View at Google Scholar · View at Scopus
  19. F. C. Arnett, J. D. Reveille, R. Goldstein et al., “Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis,” Arthritis and Rheumatism, vol. 39, no. 7, pp. 1151–1160, 1996. View at Publisher · View at Google Scholar · View at Scopus
  20. J. D. Reveille, D. Owerbach, R. Goldstein, R. Moreda, R. A. Isern, and F. C. Arnett, “Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma),” Journal of Clinical Investigation, vol. 89, no. 4, pp. 1208–1213, 1992. View at Google Scholar · View at Scopus
  21. C. Marguerie, C. C. Bunn, J. Copier et al., “The clinical and immunogenetic features of patients with autoantibodies to the nucleolar antigen PM-Scl,” Medicine, vol. 71, no. 6, pp. 327–336, 1992. View at Google Scholar · View at Scopus
  22. P. A. Morel, H. J. Chang, J. W. Wilson et al., “Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRw11 allele,” Human Immunology, vol. 40, no. 2, pp. 101–110, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Briggs, C. Stephens, R. Vaughan, K. Welsh, and C. Black, “A molecular and serologic analysis of the major histocompatibility complex and complement component C4 in systemic sclerosis,” Arthritis and Rheumatism, vol. 36, no. 7, pp. 943–954, 1993. View at Google Scholar · View at Scopus
  24. G. C. Fanning, K. I. Welsh, C. Bunn, R. du Bois, and C. M. Black, “HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients,” British Journal of Rheumatology, vol. 37, no. 2, pp. 201–207, 1998. View at Google Scholar · View at Scopus
  25. J. D. Reveille, M. Fischbach, T. McNearney et al., “Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants,” Seminars in Arthritis and Rheumatism, vol. 30, no. 5, pp. 332–346, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Langevitz, D. Buskila, D. D. Gladman, G. A. Darlington, V. T. Farewell, and P. Lee, “HLA alleles in systemic sclerosis: association with pulmonary hypertension and outcome,” British Journal of Rheumatology, vol. 31, no. 9, pp. 609–613, 1992. View at Google Scholar · View at Scopus
  27. A. Santaniello, G. Salazar, S. Lenna et al., “HLA-B35 upregulates the production of endothelin-1 in HLA-transfected cells: a possible pathogenetic role in pulmonary hypertension,” Tissue Antigens, vol. 68, no. 3, pp. 239–244, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Lenna, D. M. Townsend, F. K. Tan et al., “HLA-B35 upregulates endothelin-1 and downregulates endothelial nitric oxide synthase via endoplasmic reticulum stress response in endothelial cells,” Journal of Immunology, vol. 184, no. 9, pp. 4654–4661, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. F. C. Arnett, “HLA and autoimmunity in scleroderma (systemic sclerosis),” International Reviews of Immunology, vol. 12, no. 2–4, pp. 107–128, 1995. View at Google Scholar · View at Scopus
  30. J. Whyte, C. Artlett, G. Harvey et al., “HLA-DQB1 associations with anti-topoisomerase-1 antibodies in patients with systemic sclerosis and their first degree relatives,” Journal of Autoimmunity, vol. 7, no. 4, pp. 509–520, 1994. View at Publisher · View at Google Scholar · View at Scopus
  31. F. C. Gilchrist, C. Bunn, P. J. Foley et al., “Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP,” Genes and Immunity, vol. 2, no. 2, pp. 76–81, 2001. View at Google Scholar · View at Scopus
  32. E. Carwile LeRoy, C. Black, R. Fleischmajer et al., “Scleroderma (systemic sclerosis): classification, subsets and pathogenesis,” Journal of Rheumatology, vol. 15, no. 2, pp. 202–205, 1988. View at Google Scholar · View at Scopus
  33. H. Poormoghim, M. Lucas, N. Fertig, and T. A. Medsger Jr, “Systemic sclerosis sine scleroderma: demographic, clinical, and serologic factors and survival in forty-eight patients,” Arthritis Rheum, vol. 43, pp. 444–451, 2000. View at Publisher · View at Google Scholar
  34. A. Ramirez and J. Varga, “Pulmonary arterial hypertension in systematic sclerosis: clinical manifestations, pathophysiology, evaluation, and management,” Treatments in Respiratory Medicine, vol. 3, no. 6, pp. 339–352, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. N. K. Harrison, A. R. Myers, B. Corrin et al., “Structural features of interstitial lung disease in systemic sclerosis,” American Review of Respiratory Disease, vol. 144, no. 3, pp. 706–713, 1991. View at Google Scholar · View at Scopus